Sodium Bicarbonate Injection

1. Treat metabolic acidosis. This product increases the concentration of carbonate in plasma and neutralizes hydrogen ions, thereby correcting acidosis. 2. Alkalinize urine. As the pH value increases after the concentration of bicarbonate in urine increases, uric acid, sulfonamide drugs and hemoglobin are not easy to form crystals or aggregate in urine. 3. Acid antacid. Oral administration can quickly neutralize or buffer gastric acid without directly affecting gastric acid secretion. Therefore, the pH in the stomach increases rapidly to relieve the symptoms caused by high gastric acid.

The main ingredient is sodium bicarbonate.

1. Treatment of metabolic acidosis. For the treatment of mild to moderate metabolic acidosis, oral administration is preferred. Severe metabolic acidosis should be treated by intravenous drip, such as severe kidney disease, circulatory failure, cardiopulmonary resuscitation, extracorporeal circulation, severe primary lactic acidosis, diabetic ketoacidosis, etc. 2. Alkalize urine. Used for the prevention of uric acid kidney stones, reducing the nephrotoxicity of sulfonamide drugs, and acute hemolysis to prevent hemoglobin deposition in the renal tubules. 3. As an antacid, it treats symptoms caused by excessive gastric acid. 4. Intravenous drip has a non-specific therapeutic effect on certain drug poisonings, such as poisoning by barbiturates, salicylates and methanol. However, this product is contraindicated for gastric lavage when swallowed in case of strong acid poisoning, because this product reacts with strong acid to produce a large amount of carbon dioxide, which leads to acute gastric dilatation or even gastric rupture.

1. Metabolic acidosis, intravenous drip, the required dose is calculated according to the following formula: Alkalinity (mmol) = (-2.3-actually measured BE value) x 0.25 x body weight (kg), or alkali (mmol) = normal CO2CP-actually measured CO2C. (mmol) x 0.25 x body weight (kg). Unless the body loses bicarbonate, generally give 1/3 to 1/2 of the calculated dose first, and complete the drip within 4 to 8 hours. 2. During cardiopulmonary resuscitation, 1mmol/kg is used for the first time, and the dosage is adjusted according to the results of blood gas analysis (each 1g of sodium bicarbonate is equivalent to 12mmol bicarbonate). 3. Alkalinization of urine, adults: intravenous drip, 2-5mmol/kg, complete the drip within 4-8 hours. 4. The following issues should also be noted for intravenous medication: The concentration range for intravenous application is 1.5% (isotonic) to 8.4%; it should start with a small dose, and the additional dose should be determined according to the changes in blood pH and bicarbonate concentration; large-scale intravenous infusion in a short period of time can cause severe alkalosis, hypokalemia, and hypocalcemia. When the dosage exceeds 10ml of hypertonic solution per minute, it can cause hypernatremia, decreased cerebrospinal fluid pressure, and even intracranial hemorrhage, which is more likely to occur in newborns and children under 2 years old. Therefore, when infusing a 5% solution, the speed should not exceed 8mmol of sodium per minute. However, during cardiopulmonary resuscitation, due to the presence of fatal acidosis, rapid intravenous infusion should be given.

1. When a large amount of intravenous injection is given, arrhythmia, muscle cramps, pain, abnormal fatigue and weakness may occur, mainly due to hypokalemia caused by metabolic alkalosis. 2. When the dose is too large or there is renal insufficiency, edema, mental symptoms, muscle pain or convulsions, slow breathing, bad taste in the mouth, abnormal fatigue and weakness may occur, mainly due to metabolic alkalosis. 3. Long-term use may cause frequent urination, urgency, persistent headache, loss of appetite, nausea and vomiting, abnormal fatigue and weakness, etc.

1. When a large amount of intravenous injection is given, arrhythmia, muscle cramps, pain, abnormal fatigue and weakness may occur, mainly due to hypokalemia caused by metabolic alkalosis. 2. When the dose is too large or there is renal insufficiency, edema, mental symptoms, muscle pain or convulsions, slow breathing, bad taste in the mouth, abnormal fatigue and weakness may occur, mainly due to metabolic alkalosis. 3. Long-term use may cause frequent urination, urgency, persistent headache, loss of appetite, nausea and vomiting, abnormal fatigue and weakness, etc.

Precautions for children: For the treatment of acidosis, refer to the adult dose. During cardiopulmonary resuscitation, the first intravenous injection is 1mmol/kg of body weight, and the dosage is adjusted according to the results of blood gas analysis. Precautions for pregnancy and lactation: 1. Long-term or large-scale use can cause metabolic alkalosis, and excessive sodium load can cause edema, etc. Pregnant women should use it with caution. 2. This product can be secreted through breast milk, but there is no relevant information on its effects on infants. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

1. When used in combination with adrenocortical hormones (especially those with strong mineralocorticoid effects), adrenocorticotropic hormones, and androgens, hypernatremia and edema are likely to occur. 2. When used in combination with amphetamine and quinidine, the latter two are excreted less through the kidneys, and toxic effects are likely to occur. 3. When used in combination with anticoagulants such as warfarin and M cholinesterase drugs, the absorption of the latter is reduced. 4. When used in combination with calcium-containing drugs, milk and dairy products, milk-alkali syndrome may occur. 5. When used in combination with H2 receptor antagonists such as cimetidine and ranitidine, the absorption of the latter is reduced. 6. When used in combination with potassium-excreting diuretics, the risk of hypochloremic alkalosis is increased. 7. This product can alkalinize urine and affect the excretion of ephedrine by the kidneys, so the dose of ephedrine should be reduced when used in combination. 8. The increase in sodium load increases the excretion of lithium by the kidneys, so when used in combination with lithium preparations, the dosage of lithium preparations should be adjusted as appropriate. 9. Alkalinizing urine can inhibit the conversion of methenamine into formaldehyde, thereby inhibiting the latter's therapeutic effect, so it is not recommended to use the two drugs together. 10. This product can increase the excretion of salicylic acid preparations by the kidneys by alkalizing urine.

Keep tightly closed.

10ml:0.5g

Harbin Pharm. Group Sanjing Pharmaceutical Co., Ltd.

• Founded in:

  2015-03-13

• Address:

  No. 76, Hengshan Road, Nangang Central District, Harbin Economic Development Zone

• Tax NO.:

  91230199301153895D

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view